Late-Onset Cold Agglutinin Syndrome Following Nivolumab Therapy: A Delayed Immune-Related Adverse Event with Masked Hemolysis – A Case Report
Case Reports in Oncology · 22.08.2026 · 19 (1) · 1485-1492
DOI: 10.1159/cro/abzag012 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Oncology, online erschienen am 22.08.2026. Verfasst von Hüseyin İflazoğlu und 1 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Cold agglutinin syndrome (CAS) is a secondary form of cold antibody-mediated autoimmune hemolytic anemia. Immune checkpoint inhibitor-associated CAS is exceedingly uncommon and poses particular diagnostic challenges in critically ill patients. Case Presentation: A 66-year-old male with metastatic squamous cell lung carcinoma was admitted to the intensive care unit (ICU) for respiratory failure, with a course complicated by sepsis and continuous renal replacement therapy (CRRT). On ICU day 24, hemoglobin-hematocrit (Hb-Hct) discordance was identified; peripheral blood smear confirmed erythrocyte agglutination. Direct antiglobulin testing (DAT) revealed C3d positivity with negative IgG, and the cold agglutinin titer was 1/64. Total and indirect bilirubin were elevated. Quantitative immunoglobulin concentrations did not demonstrate an elevated IgM level; however, serum protein electrophoresis, immunofixation, and bone marrow examination could not be completed, so an occult clonal B-cell disorder could not be definitively excluded. The clinical presentation was considered more consistent with probable secondary CAS than with primary cold agglutinin disease (CAD). CAS was diagnosed as a delayed immune-related adverse event (irAE) approximately 14 months after nivolumab discontinuation. No recognized infectious trigger classically associated with cold agglutinin-mediated hemolysis was identified. A malignancy-associated mechanism could not be completely excluded but was considered less likely. Causality was assessed using the Naranjo Adverse Drug Reaction Probability Scale (score: 6; probable adverse drug reaction). Rituximab was withheld due to refractory sepsis and hemodynamic instability. Management consisted of active thermal control (CRRT circuit temperature maintained at 38°C), warmed erythrocyte transfusions, and avoidance of cold exposure.
Conclusion
This case highlights that CAS may emerge as a delayed irAE following nivolumab therapy. Hb-Hct discordance should be recognized as an early diagnostic clue when classical hemolytic markers are masked. Active thermal control during CRRT represents a practical strategy to limit hemolysis.
Zitieren
APA
İflazoğlu, H., & İnal, V. (2026). Late-Onset Cold Agglutinin Syndrome Following Nivolumab Therapy: A Delayed Immune-Related Adverse Event with Masked Hemolysis – A Case Report. Case Reports in Oncology, 19(1), 1485-1492. https://doi.org/10.1159/cro/abzag012
Vancouver
İflazoğlu H, İnal V. Late-Onset Cold Agglutinin Syndrome Following Nivolumab Therapy: A Delayed Immune-Related Adverse Event with Masked Hemolysis – A Case Report. Case Reports in Oncology. 2026;19(1):1485-1492. doi:10.1159/cro/abzag012
BibTeX
@article{flazolu2026,
author = {İflazoğlu, Hüseyin and İnal, Volkan},
title = {Late-Onset Cold Agglutinin Syndrome Following Nivolumab Therapy: A Delayed Immune-Related Adverse Event with Masked Hemolysis – A Case Report},
journal = {Case Reports in Oncology},
year = {2026},
volume = {19},
number = {1},
pages = {1485--1492},
doi = {10.1159/cro/abzag012}
}
EUVIMED